Galecto, Inc.
GLTO$12M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaBOSTON
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
GLTO News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
GB1211
Non-Small Cell Lung Cancer
GB2064
Myelofibrosis
GB0139
Idiopathic Pulmonary Fibrosis (IPF)
Inhaled TD139
Idiopathic Pulmonary Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GB1211 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
GB2064 | Phase 2 | Myelofibrosis | - | - |
GB0139 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | - | - |
Inhaled TD139 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply